Alamea Verwaltungs GmbH Decreases Position in GeneDx Holdings Corp. $WGS

Alamea Verwaltungs GmbH decreased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 5.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 185,989 shares of the company’s stock after selling 9,999 shares during the period. GeneDx makes up about 16.4% of Alamea Verwaltungs GmbH’s portfolio, making the stock its 2nd biggest position. Alamea Verwaltungs GmbH’s holdings in GeneDx were worth $24,190,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp increased its stake in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of GeneDx during the 4th quarter valued at $27,000. Quarry LP boosted its holdings in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares in the last quarter. Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx during the 4th quarter valued at $33,000. Finally, Greenline Wealth Management LLC acquired a new stake in shares of GeneDx during the 4th quarter valued at $33,000. Institutional investors own 61.72% of the company’s stock.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Insider Activity

In related news, Director Casdin Capital, Llc bought 185,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the acquisition, the director owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. This represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith A. Meister acquired 533,758 shares of the stock in a transaction dated Thursday, May 7th. The stock was acquired at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the transaction, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This represents a 16.53% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 2,256,420 shares of company stock worth $93,144,340 and have sold 77,287 shares worth $5,153,215. 29.60% of the stock is currently owned by insiders.

GeneDx Stock Down 1.8%

Shares of WGS opened at $59.92 on Friday. The company has a market capitalization of $1.78 billion, a PE ratio of -22.36 and a beta of 1.96. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The stock’s 50-day moving average price is $54.95 and its two-hundred day moving average price is $90.19. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the previous year, the firm posted ($0.23) earnings per share. On average, analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on WGS. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a “buy” rating in a report on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Finally, Guggenheim cut their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.